Genomic diversity and antimicrobial resistance of *Prevotella* spp. isolated

from chronic lung disease airways

Kasey A. Webb^{1,2}, Olusola Olagoke^{1,2}, Timothy Baird^{2,3}, Jane Neill³, Amy Pham⁴, Timothy J. Wells⁴, Kay A. Ramsay^{5†}, Scott C. Bell^{5,6,7}, Derek S. Sarovich^{1,2*#}, and Erin P. Price^{1,2*#}

¹GeneCology Research Centre, University of the Sunshine Coast, Sippy Downs, QLD, Australia

²Sunshine Coast Health Institute, Birtinya, QLD, Australia

³Sunshine Coast Hospital and Health Service, Sunshine Coast University Hospital, Birtinya, QLD, Australia

⁴University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD, Australia

⁵QIMR Berghofer Medical Research Institute, Herston, QLD, Australia

⁶Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Chermside, QLD, Australia

⁷Translational Research Institute, Woolloongabba, QLD, Australia

[†]Present address: Child Health Research Centre, The University of Queensland, Centre for Children's Health Research, South Brisbane, QLD, Australia

*Authors contributed equally to this work

[#]Corresponding authors

University of the Sunshine Coast, Locked Bag 4, Maroochydore DC, Qld, 4558, Australia

Email: dsarovich@usc.edu.au; Ph: +61 5456 3748

Email: eprice@usc.edu.au; Ph: +61 7 5456 5568

Key Words: *Prevotella*, genomics, cystic fibrosis, chronic obstructive pulmonary disease, respiratory infections, polymicrobial infections, real-time PCR, diagnostics, sputum

1 Data summary

- 2 Thirty-five Prevotella spp. genomes generated in this study are available in the Sequence Read
- 3 Archive (SRA) and GenBank databases under BioProject accession PRJNA742126.

4 Abstract

5 Cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) are characterised by 6 increasingly frequent acute pulmonary exacerbations that reduce life quality and length. Human 7 airways are home to a rich polymicrobial environment, including members of the obligately anaerobic 8 genus, Prevotella. Despite their commonness, surprisingly little is known about the prevalence, role, 9 genomic diversity, and antimicrobial resistance (AMR) potential of Prevotella species/strains in 10 healthy and diseased airways. Here, we used comparative genomics to develop a real-time PCR 11 assay to permit rapid Prevotella spp. quantification from cultures and clinical specimens. Assay 12 specificity was validated across a panel of Prevotella and non-Prevotella species, followed by PCR 13 screening of CF and COPD respiratory-derived cultures. Next, 35 PCR-positive isolates were 14 subjected to whole-genome sequencing. Of eight identified species, P. histicola, P. melaninogenica, 15 P. nanceiensis, P. salivae and P. denticola overlapped between participant cohorts. Phylogenomic 16 analysis revealed considerable interhost but limited intrahost diversity, suggesting patient-specific 17 lineages in the lower airways, probably from oral cavity aspirations. Correlation of phenotypic AMR 18 profiles with AMR gene presence identified excellent correlation between tetQ presence and 19 decreased doxycycline susceptibility, and ermF presence and decreased azithromycin susceptibility 20 and clindamycin resistance. AMR rates were higher in the CF isolates, reflecting greater antibiotic use 21 in this cohort. All tested Prevotella isolates were tobramycin-resistant, providing a potential selection 22 method to improve Prevotella culture retrieval rates. Our addition of 35 airway-derived Prevotella 23 genomes to public databases will enhance ongoing efforts to unravel the role of this diverse and 24 enigmatic genus in both chronic respiratory diseases and healthy lungs.

25 Introduction

26 Chronic lung diseases are a leading cause of global healthcare burden and early mortality^{1,2}. Although 27 cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) have fundamentally different 28 aetiologies, both are characterised by impaired airway mucociliary clearance, which provides a 29 favourable environment for microbial colonisation and persistence, and a challenging environment for 30 pathogen eradication. Infections are the primary contributor in CF and COPD respiratory 31 exacerbations (i.e. acute worsening of symptoms), during which inflammation and irreversible airway 32 damage can occur³. In CF, 80-95% of deaths are associated with acute exacerbations and chronic bacterial infections, which eventually lead to respiratory failure⁴. In COPD, bacterial, viral, and fungal 33 34 respiratory infections trigger ~70-80% exacerbation events⁵. Despite their crucial role in reducing 35 quality and length of life, there remain major gaps in understanding the collective microbial drivers 36 associated with CF and COPD pathophysiology. 37 Routine culture-based diagnosis of CF and COPD exacerbations often overlooks more fastidious or 38 uncultivable members within the airway microbiome, leaving a gap in fully understanding the complex composition and activity of CF and COPD microbiomes^{6,7}. Culture-independent techniques like 39 40 metataxonomics (e.g. 16S rRNA amplicon sequencing), metagenomics, and metatranscriptomics are 41 gaining traction as adjuncts or potentially even alternatives to culture due to their ability to identify a 42 much broader spectrum of microbes, including uncultured taxa, resulting in better diagnosis, more informed treatment strategies, and improved clinical outcomes⁸⁻¹⁰. In addition to identifying well-43 44 characterised microbes associated with respiratory exacerbations, molecular methods have unveiled 45 previously unidentified microbial communities in chronic lung disease airways, including a diverse anaerobic microbiome¹¹. 46 The Prevotella genus, which comprises ≥51 species^{12,13}, is a common and often abundant obligate 47 anaerobe in the human body, including in CF and COPD airways^{11,14-19}. Despite its commonness, the 48 role of *Prevotella* in disease progression is incompletely understood in CF¹¹, and even less so in 49 50 COPD. Several studies investigating *Prevotella* spp. in airway disease, particularly CF, have yielded

51 conflicting evidence. Some studies suggest a likely pathogenic role^{18,20}, whereas others have shown

- 52 no role²¹, or even a benefit when *Prevotella* spp. are abundant^{22,23}. A major contributor to these
- 53 equivocal findings is that culture-dependent and metaxonomic methods largely fail to identify

microbes to the species and strain level^{7,13,24,25}. As such, only a handful of *Prevotella* studies have 54 55 described potential species- or strain-specific mechanisms in airway disease pathogenesis. 56 The number of *Prevotella* genomes has been steadily increasing in recent years. However, in 57 comparison to more intensely studied CF and COPD airway organisms, there is a relative paucity of 58 respiratory Prevotella genomic data in public databases. Most Prevotella species contain only a single representative (and many were generated from a single metagenomic study)²⁶, leading to issues with 59 60 correct species assignments from metagenome-assembled genomes. Further, most genomic studies 61 have concentrated on known pathogens in oral (e.g. P. intermedia and P. nigrescens), gut (e.g. P. copri), and urogenital (e.g. P. bivia) microbiomes²⁷⁻²⁹. There is a lack of knowledge about the 62 63 Prevotella spp. commonly found in airways, particularly in COPD. Insufficient resolution to the species 64 and strain level has limited our understanding of Prevotella spp. diversity, function, evolution, and 65 antimicrobial resistance (AMR) potential within CF and COPD airways during exacerbations and stability^{13,24}. 66 67 Here, we first used a comparative genomics approach to design and optimise a novel real-time PCR 68 assay to permit the rapid, cost-effective, and specific detection of Prevotella spp. from both culture 69 and clinical specimens. Next, 43 CF-COPD sputa and bronchial washings were cultured to isolate 70 individual Prevotella strains for whole-genome sequencing (WGS) characterisation, followed by 71 genomic analyses to determine species identity, strain relatedness, and within-host evolution. 72 Cultured isolates were subject to AMR testing across 11 clinically-relevant antibiotics, and correlated 73 with AMR determinants identified by WGS. Finally, Prevotella morphological characteristics were 74 assessed for their diagnostic value.

75 Methods

88

76 Ethics statement. Collection and analysis of clinical samples was approved by The Prince Charles 77 Hospital (TPCH) Human Research Ethics Committee (HREC), project IDs HREC/13/QPCH/127 (CF 78 samples) and HREC/2019/QPCH/48013 (COPD samples). Site-specific approvals were obtained for 79 CF recruitment at TPCH, Brisbane, Australia, and COPD recruitment at Sunshine Coast Hospital and 80 Health Service, Sunshine Coast, Australia. All participants provided written consent. 81 Sample collection and storage. A total of 36 CF sputa were obtained from 21 expectorating adults 82 with CF presenting at TPCH Adult CF Centre between 2017 and 2019. Seven participants provided 83 multiple sequential sputa (Table S1). Sputa were stored non-anaerobically at -80°C in Luria-Bertani 84 broth containing 20% glycerol, and stored for 2-24 months prior to microbiological assessment. A total 85 of 32 COPD sputa (n=21) or bronchial washings (BWs; n=11) were obtained from 21 current/former 86 tobacco smokers during community or in-hospital consult at Sunshine Coast Hospital and Health 87 Service in 2020 (Table S1). Five participants provided multiple sequential sputa (Table S1). BWs

89 from both the tumour site (biopsied after BW collection) and approximately the same position in the

were taken from participants with suspected lung cancer, with most collected as paired specimens

90 non-tumour contralateral (contra) lung. BWs were pelleted at 4°C and ~9,300 x g for 15 min, with

supernatant removed and pellet resuspended in 800 µL phosphate-buffered saline. COPD samples

92 were stored within 12-36 hours of collection using the same parameters as described for the CF

93 specimens, and microbiologically processed within ~2 weeks of collection. Clinical and antibiotic

94 treatment regimens were recorded (**Table S1**) to permit correlation with *Prevotella* AMR profiles.

95 <u>Microbiological preparation and storage</u>. Clinical samples were directly subcultured onto anaerobic

96 blood medium containing nalidixic acid and vancomycin (Thermo Fisher Scientific, Seventeen Mile

97 Rocks, QLD, Australia; cat. no. PP2065). Plates were incubated anaerobically at 37°C in an

98 AnaeroPack 2.5L jar with an AnaeroGen 2.5L gas pack (Thermo Fisher) for 2-5 days. Isolates were

subcultured based on different morphotypes, with a second subculture for purity onto non-selective

anaerobic blood medium (Thermo Fisher; cat. no. PP2039). *Prevotella* real-time PCR-positive isolates

101 were again sub-cultured onto non-selective anaerobic blood medium for purity and stored non-

102 anaerobically at -80°C in 1mL Luria-Bertani broth containing 20% glycerol. Additionally, WGS-

103 confirmed, representative *Prevotella* isolates derived from CF samples were cultured from glycerol

104 stocks onto both polyvitaminic-supplemented chocolate agar (PVCA; Edwards Group, Murrarie, QLD,

Australia; cat. no. 1065) and non-selective anaerobic blood medium to assess phenotypic differences
 over a 10-day period.

107 DNA extractions. DNA of presumptive Prevotella spp. isolates was initially extracted using 5% chelex-108 100³⁰ (Bio-Rad, Gladesville, NSW, Australia), heat-treated at 95°C for 20 min, and diluted to 1:50 with 109 molecular-grade H₂O prior to PCR. DNA for WGS was extracted using the Gram-positive bacteria 110 protocol of the DNeasy Blood and Tissue Kit (Qiagen, Chadstone, VIC, Australia). Qiagen extractions 111 were quality-checked and quantified using the NanoDrop 2000 spectrophotometer (Thermo Fisher). 112 Clinical specimens were extracted using 3 parts TRI Reagent LS (Sigma-Aldrich, North Ryde, NSW, 113 Australia) to 1 part specimen, 30µL 0.1M 2-mercaptoethanol, and ~ 100µL equal mixture of 0.1 and 114 0.5mm zirconia beads (Daintree Scientific, St Helens, TAS, Australia). Homogenisation comprised 115 eight rounds of 30 sec bead beating (each round followed by 30-60 sec on wet ice) using the 116 'medium' setting of the Minilys tissue homogeniser (Bertin Instruments, Montigny-le-Bretonneux, 117 France). After removal of the RNA aqueous phase, back extraction was performed on the interphase and proteinaceous phase³¹ to isolate total DNA. 118 119 Prevotella spp. real-time PCR assay design. Due to high levels of genetic variability among Prevotella spp., the highly conserved 16S-23S rRNA genes were targeted. A custom BLAST³² 2.10.2+ database 120 121 was created using 60 Prevotella spp. genomes encompassing 26 assigned and nine unassigned 122 species (Table S2). Discontiguous MegaBLAST was carried out against the 4.8kb P. intermedia

123 ATCC 25611 23S-16S rRNA locus (GenBank accession CP019300.1, coordinates 63001-67800)

124 using the custom BLAST database. BLAST .xml outputs were aligned and visualised using Geneious

125 Prime vR10. A highly conserved area within the *Prevotella* spp. 16S rRNA gene was assessed further

126 to identify potential PCR oligos, with conserved regions possessing several single nucleotide

127 polymorphisms (SNPs) in other microbes exploited during probe and primer design. Primers and

128 probes were initially assessed using Primer Express v3.0 (Applied Biosystems) to test melting

129 temperature (T_m) suitability in Black Hole Quencher format (primer $T_m=60^{\circ}$ C; probe $T_m=70^{\circ}$ C). All

130 candidate primers and probes were assessed for self- and hetero-dimer formation using Beacon

- 131 Designer (<u>http://www.premierbiosoft.com/qpcr/</u>), with oligo sequences requiring a ΔG value of >-4
- 132 kcal/mol. Candidate oligos were subsequently subjected to NCBI Microbial Nucleotide BLAST and

133 Nucleotide BLAST searches to confirm specificity for *Prevotella* spp.. As the 16S region is highly

134 conserved in all bacteria, the forward primer incorporated a penultimate mismatch to prevent non-

specific binding to closely related non-*Prevotella* taxa. Additionally, a BHQplus probe (CAL Fluor Gold
540-pdCApdUApdUpdCGApdCGGGGggUGG-BHQ1; Biosearch Technologies, Petaluma, California,
USA) was included to enhance specificity and to permit assay use on clinical specimens. Forward (5'TTCTCCAGtCCAGGATGTGtC-3') and reverse (5'-CGGGGATAACAGGCTGATCC-3') primers were
manufactured by Macrogen Inc. (Geumcheon-gu, Seoul, South Korea), with lowercase nucleotides
representing intentional mismatches.

- 141 Real-time PCRs were carried out on a Bio-Rad CFX96 thermocycler using 0.35µM primers and probe,
- 142 1X Sso Advanced Universal mastermix (Bio-Rad), molecular-grade H2O, and 1µL template, to a 5µL
- final volume. Thermocycling parameters were: 95°C for 2 min, followed by 45 cycles of 95°C for 5 sec
- and 60° C for 20 sec. DNA integrity for all clinical samples was assessed via amplification towards β -
- 145 globin³³ (human) and universal 16S rRNA³⁴ (bacteria); the universal 16S rRNA assay was also used
- to verify bacterial culture DNA integrity, and a panfungal assay (O. Olagoke and E. Price,
- 147 unpublished) was used to verify *Candida* spp. DNA integrity.
- 148 Real-time PCR assay optimisation and specificity testing. The final optimised real-time PCR assay
- 149 was assessed for accuracy by running against a diversity panel of six *Prevotella* spp. (one each of *P.*
- 150 copri, P. denticola, P. histicola, P. melaninogenica, P. nigrescens, and P. salivae), 1 human DNA
- 151 sample, and 40 non-Prevotella spp., with a focus on common respiratory tract microbes (n=1 unless
- 152 otherwise stated): Achromobacter xylosoxidans, Bordetella bronchiseptica, Burkholderia cepacia,
- 153 Burkholderia territorii, Burkholderia thailandensis, Candida albicans, Candida dubliniensis,
- 154 Cupriavidus metallidurans, Enterobacter aerogenes, Enterobacter cloacae (n=3), Enterococcus
- 155 raffinosus, Klebsiella oxytoca, Klebsiella pneumoniae (n=2), Lacticaseibacillus paracasei (n=2),
- 156 Pseudomonas aeruginosa (n=12), Staphylococcus aureus (n=3), Staphylococcus haemolyticus,
- 157 Stenotrophomonas maltophilia, Veillonella atypica (n=3), Veillonella parvula, and Veilonella dispar. All
- 158 DNA was normalised spectrophotometrically to 2ng/µL prior to PCR.
- 159 Limits of detection (LoD) and quantification (LoQ) for the optimised assay were determined using P.
- 160 *melaninogenica* LMG 28911 DNA, using serial dilutions of $4ng/\mu L$ to $4 \times 10^{-6} ng/\mu L$ across 8 replicates
- 161 per dilution. The upper and lower LoD/LoQ limits were determined as described elsewhere³⁵. Genome
- 162 equivalence was determined based on an average *Prevotella* genome size of 3.29Mbp and a single
- 163 copy of the 16S rRNA gene.

<u>16S rRNA gene diversity profiling (metataxonomics)</u>. Metataxonomics was performed by the
 Australian Genome Research Facility (AGRF; Melbourne, VIC, Australia) for total CF DNA and ID
 Genomics (Seattle, WA, USA) for total COPD DNA using standard protocols for V3-V4 (i.e. 341F and
 806R) primers.
 Antimicrobial resistance (AMR) profiling. Twenty-eight glycerol-stocked *Prevotella* cultures were

169 subcultured onto non-selective anaerobic blood medium, or PVCA where no growth was obtained on

170 the anaerobic medium (*n*=2), and incubated at 37°C under anaerobic conditions for 2-3 days. Cultures

171 were then resuspended into phosphate-buffered saline to OD₆₀₀=0.75 (Biochrom, Cambridge, UK).

172 Six supplemented chocolate plates per isolate were lawn-inoculated with the OD-normalised cells as

173 previously described³⁶, and antibiotic discs (Edwards Group) towards 11 antibiotics (amoxicillin-

174 clavulanate [AMC] 30µg; azithromycin [AZM] 15ug; ceftazidime [CAZ] 30µg; chloramphenicol [CHL]

175 30µg; clindamycin [CLI] 2µg; doxycycline [DOX] 30µg; imipenem [IPM] 30µg; meropenem [MEM]

176 10µg; metronidazole [MZ] 5µg; piperacillin-tazobactam [TZP] P:100µg, TZ:10µg; tobramycin [TOB]

177 10µg) were placed onto inoculated plates. Plates were incubated at 37°C under anaerobic conditions

178 for 48h prior to measurement. As no disc diffusion reference ranges exist for *Prevotella* spp., growth

179 up to the disc (i.e. 6mm diameter) was denoted as AMR, which underestimates the true rate of AMR

180 but provides a clear cut-off for unambiguous interpretation. Diameters ≤30mm for any antibiotic were

181 denoted as reduced susceptibility.

182 <u>Whole-Genome Sequencing (WGS)</u>. PCR-confirmed *Prevotella* isolates were sequenced using the

183 Illumina HiSeq 2500 platform with 150bp seqWell plexWell paired-end read chemistry at AGRF.

184 <u>Genome assemblies</u>. Prevotella genomes were de novo assembled using default Microbial Genome

185 Assembly Pipeline v1.1 parameters (<u>https://github.com/dsarov/MGAP---Microbial-Genome-</u>

186 <u>Assembler-Pipeline</u>) or SPAdes³⁷.

187 <u>Speciation and mixture analysis</u>. *Prevotella* spp. assemblies were initially assessed for species

188 identification and mixtures using the Ribosomal MLST³⁸ tool. Isolates containing mixtures of

189 *Prevotella* and non-*Prevotella* species (*n*=8), or multiple *Prevotella* species (*n*=1) (**Table S3**), were

190 excluded from further investigation.

Phylogenetic analysis. A custom BLAST database of *Prevotella* genomes (*n*=234) comprising taxa of
 known (*n*=56) and unassigned (*n*=40) species, and including non-mixed isolate genomes sequenced

in this study (*n*=35 genomes), was created using BLAST 2.10.2+. BLAST analysis was performed
against the full-length 1,534bp *P. melaninogenica* 16S rRNA gene (RefSeq ID: NC_014371.1; bases
962,784-964,317). Hits were filtered to remove redundancies (final *n*=199), and reads aligned using
ClustalX2 v2.1³⁹. A dendogram was constructed using the neighbour-joining method and the TamuraNei model and viewed in FigTree v1.4.0 (<u>http://tree.bio.ed.ac.uk/software/figtree/</u>) using midpoint
rooting.
Phylogenomics. Variant identification of our CF-COPD genomes ('SCHI' prefix) was performed using

- 200 SPANDx v4.0⁴⁰. Reference genomes for *P. denticola*, *P. histicola*, *P. melaninogenica*, *P. nanceiensis*,
- and P. salivae were downloaded from GenBank (IDs GCA_000193395.1, GCA_000234055.1,
- 202 GCA_000144405.1, GCA_000163055.2, and GCA_000477535.1, respectively) and used for read
- 203 mapping. Synthetic reads were generated from GenBank genome assemblies for P. denticola
- 204 (GCA_000191765.2, GCA_000759205.1, GCA_000421205.1, GCA_003515045.1, and
- 205 GCA_900454835.1), P. histicola (GCA_000613925.1), P. melaninogenica (GCA_000163035.1,
- 206 GCA_000759305.1, GCA_002208725.2, GCA_003609775.1, and GCF_000517825.1), P.
- 207 nanceiensis (GCA_000517825.1 and GCA_000613985.1), and P. salivae (GCA_000185845.1 and
- 208 GCA_902374235.1) using ART v2.3.7⁴¹.
- 209 Illumina reads for *P. histicola* T05-04T (SRR1518629) and *P. nanceiensis* ADL-403 (SRR755359)
- 210 were downloaded from the Sequence Read Archive database and quality filtered using Trimmomatic
- 211 v0.39⁴² parameters described elsewhere⁴³. The resulting biallelic, orthologous SNP matrix generated
- 212 by SPANDx was phylogenetically reconstructed using the maximum parsimony heuristic function of
- 213 PAUP* v4.0a (build 168). Phylogenies were visualised in FigTree; all trees were midpoint-rooted.
- 214 <u>AMR determinant analysis</u>. The Resistance Gene Identifier v5.1.1, which employs the Comprehensive
- 215 Antibiotic Resistance Database (CARD) v3.1.0⁴⁴, was used to identify putative AMR determinants.

216 Results and Discussion

217 Molecular typing approaches have been instrumental in unveiling previously untapped microbial 218 diversity in both healthy and diseased lungs. Using these techniques, Prevotella spp. have consistently been identified as one of the most prevalent taxa in CF and COPD airways^{10,14,19}. 219 220 However, most studies to date have employed 16S metataxonomics (usually targeting the V3-V4 221 gene region), which only characterises Prevotella to the genus level, despite species and strain 222 resolution being fundamental to unravelling the role of these anaerobes in chronic lung disease. To 223 address this knowledge gap, our study used a combination of culture-dependent and -independent 224 methods to examine the genomic and phenotypic diversity, and prevalence, of Prevotella spp. present 225 in CF and COPD airways.

226 We first used a comparative genomics-guided approach to develop an accurate real-time PCR assay 227 to enable the rapid detection of *Prevotella* spp., to the exclusion of all other organisms, both from 228 cultures and clinical specimens. Our PCR assay was reasonably sensitive, with LoD and LoQ both 229 being 400fg/µL, or 111 genome equivalents (Figure 1). When tested against a diverse panel of 47 230 microbial and human DNA, the PCR demonstrated 100% specificity, amplifying all six tested 231 Prevotella species, but none of the non-Prevotella spp. DNA and 10 no-template controls. On clinical 232 specimens, the PCR identified Prevotella in 81% CF and 71% COPD participants, and in 81% CF and 233 66% COPD specimens (Table 1). This difference in detection rates between diseases was expected 234 given the generally lower total bacterial load in COPD airways¹. Metataxonomics had higher 235 Prevotella sensitivity than PCR, identifying Prevotella in six PCR-negative samples, although there 236 was one false-negative (SCHI0049.C.3, which was PCR- and culture-positive); there was otherwise 237 near-perfect correlation between PCR and metataxonomics (Table S3). In the six PCR-negative 238 samples, Prevotella relative abundance was very low (0.004-0.3%; median=0.05%), indicating that 239 DNA levels were below the PCR LoD threshold. Thus, culture-independent methods are highly 240 suitable for accurate Prevotella spp. detection from polymicrobial specimens, particularly real-time 241 PCR, which is often performed upon clinical sample receipt, thereby permitting same-day detection of 242 *Prevotella* in respiratory samples.

Culture of sputa and BWs onto three different agars (anaerobic blood medium containing nalidixic
 acid and vancomycin, non-selective anaerobic blood medium, and PVCA) yielded a much lower
 Prevotella positivity rate compared with PCR and metataxonomics. Only 44% CF and 28% COPD

246 clinical specimens, respectively, were *Prevotella*-positive via culture, compared with 81% and 66% 247 using PCR, and 84% and 91% using metataxonomics (Table 1). The reduced retrieval rate in COPD 248 vs. CF can be explained by lower relative Prevotella abundance according to metataxonomics (0.3-249 74.3% [median=9.6%) for CF vs. 0.002%-36.4% [median=0.6%] for COPD). The lower prevalence of 250 Prevotella using culture is likely due to multiple factors, such as an inability of culture-independent 251 methods to distinguish viable from non-viable cells, nutritional fastidiousness, cells being in a viable 252 but non-culturable state, and outcompetition from faster-growing taxa^{9,19,22}. A prior study found that 253 four different culture media were required to recover 42 Prevotella isolates from 26 samples, and only 20 isolates were recoverable on more than one medium¹⁹. Moreover, all four media were required to 254 recover *P. melaninogenica* from all sputum samples¹⁹, suggesting that growth requirements may be 255 256 species- and strain-specific. In contrast to this prior work, we used aerobic collection and storage conditions, which likely precluded recovery of *Prevotella* taxa with poor/no aerotolerance⁴⁵. Consistent 257 258 with their fastidiousness, one P. histicola and five P. melaninogenica initially isolated in our study 259 were unable to be resuscitated from glycerol stocks upon repeated attempts, despite previously being 260 culturable. Taken together, it is probable that several Prevotella species or strains were not recovered 261 by culture in our study due to multiple factors, thereby underestimating species and strain diversity 262 within our cohorts.

263 To gain greater insight into Prevotella residing in CF and COPD airways, we performed WGS and 264 phylogenetic analysis on cultured isolates to determine species identity and strain relatedness. From 265 36 CF sputa, 27 PCR-positive Prevotella colonies were retrieved, of which 18 were Prevotella spp.; 266 the remaining nine contained a mixture of *Prevotella* and other taxa, or a mixture of multiple 267 Prevotella spp., due to insufficient subculturing for purity prior to WGS (Table S3). To avoid known 268 bioinformatic analysis issues associated with variant calling from mixtures⁴⁶, these mixed data were 269 excluded from phylogenetic analysis. Among the 18 isolates, WGS identified seven Prevotella spp.: P. 270 histicola (n=5), P. melaninogenica (n=5), P. denticola (n=3), P. nanceiensis (n=2), P. jejuni (n=1), P. 271 nigrescens (n=1), and P. salivae (n=1). Of the 17 COPD-derived isolates, none were mixed due to a 272 greater number of passages carried out to obtain purity. WGS identified six Prevotella spp.: P. 273 melaninogenica (n=8), P. histicola (n=3), P. salivae (n=3), P. buccae (n=1), P. denticola (n=1), and P. 274 nanceiensis (n=1) (**Table S3**). Despite being fundamentally different diseases, there was little 275 difference in Prevotella species found in CF and COPD, with only P. jejuni and P. nigrescens being

276 unique to CF, and P. buccae being unique to COPD. One explanation for this overlap is that the oral cavity and oropharynx are common habitats for all retrieved species, except P. jejuni⁴⁷; it is thus 277 278 possible that some strains we isolated were upper airway residents. Whilst oral cavity contamination 279 is unavoidable during respiratory secretion collection, especially for sputum, microbes can also enter 280 lower airways via small-volume oral cavity aspirations; indeed, the risk of microbial colonisation and persistence is greatly increased in mucociliary-impaired CF and COPD airways^{24,48-52}. In support of 281 282 lower airway origin, we identified Prevotella spp. in both sputa and BWs. Unlike sputa, BWs are 283 collected via bronchoscopy and thus far less prone to oral/oropharynx contamination, providing 284 greater confidence that many of our retrieved Prevotella isolates originated from the lower airways. 285 The origin of *P. jejuni* in one CF participant is somewhat perplexing. This species was first documented in the small intestine of a child with coeliac disease in 2012⁵³, and little is currently 286 287 known about the distribution of this organism in healthy and diseased niches. One possibility is that P. 288 jejuni entered the CF airways via inhalation of gastroesophageal aspirations. Alternatively, microbial 289 inter-compartment cross-talk between the lungs and gut (the 'Gut-Lung axis') via the mesenteric lymphatic system may explain its presence in the lungs⁵⁴. As a relatively new taxon, little is known 290 291 about possible mechanisms of P. jejuni pathogenesis, with more work needed to determine the 292 prevalence and virulence potential of this bacterium in both healthy and diseased airways. 293 The most frequently isolated species in our study - P. melaninogenica (37%), P. histicola (23%), P. 294 salivae (11%), P. denticola (11%), and P. nanceiensis (9%) - are common in CF^{14,15,19} and COPD²⁵ 295 airways. However, their precise role in airway disease is poorly understood due to conflicting reports 296 about their beneficial vs. pathogenic potential. For instance, P. melaninogenica, P. salivae, and P. 297 nanceiensis may inhibit non-typeable Haemophilus influenzae-induced pro-inflammatory cytokine production by lung dendritic cells⁵², increased *P. melaninogenica* prevalence in CF airways has been 298 299 associated with improved lung function¹⁵, and *P. histicola* can mute pro-inflammatory pathways triggered by *P. aeruginosa* in CF airways⁵⁵. In contrast, *P. melaninogenica* produced the greatest 300 301 variety of short-chain fatty acids (associated with inflammation) amongst five tested anaerobes¹⁸, and 302 P. denticola shares similarities in its lipid A moieties to P. intermedia (a known pathogenic species), pointing towards pro-inflammatory traits⁵⁶. Finally, certain strains of the periodontal disease-303 304 associated species, P. nigrescens, a close relative of P. intermedia, are thought to encode an 305 enzymatic cell hydrolysis mechanism that destroys tissues. Given the reported conflicting roles of

306 *Prevotella* spp. in chronic lung disease, these collective results suggest that virulence mechanisms
 307 vary among *Prevotella* strains, which requires further exploration^{57,58}. Our genomic data will assist
 308 these future efforts.

309 In our experience, metagenomic analysis tools can struggle with *Prevotella* species-level identification

310 from respiratory specimens due to a lack of accurate representative species in public databases.

311 Exemplifying this problem, few publicly available genomic data are available for *P. nanceiensis* – only

three were available at the time this study was undertaken, one of which is misclassified as *P*.

313 melaninogenica, and another as Prevotella sp. (Figure 3). Thus, our addition of three P. nanceiensis

314 genomes doubles the available P. nanceiensis data. Similarly, there are currently only a handful of

315 nonredundant *P. jejuni* genomes in public databases, and none are from lower airway specimens; our

addition *P. jejuni* SCHI0011.S.13 genome is therefore valuable for future respiratory and

317 gastroenterological studies. Taken together, our P. nanceiensis and P. jejuni genomes will help public

318 database curation efforts, and in turn, improve species identification using metagenomics.

319 To determine strain relatedness within and between participant airways, we undertook within-species

320 analyses of our P. denticola, P. histicola, P. melaninogenica, P. nanceiensis and P. salivae genomes

321 (Figure 3). Whole-genome SNP analysis revealed high levels of strain and interhost diversity in all

322 examined Prevotella species. For example, genetic variation was as high as ~72k SNPs among P.

323 *histicola* strains, an impressive feat for an organism encoding a 3Mbp genome, and *P. nanceiensis*

324 strains SCHI0010.S.3 and SCHI0011.S.12 were more closely related to strains isolated from France

325 and the US, respectively, than to other strains retrieved from other Australian participants. In contrast,

326 intrahost diversity was relatively limited (0-297 SNPs), with two instances of genetically

327 indistinguishable strains: P. histicola SCHI0034.S.5 and SCHI0034.S.6, and P. melaninogenica

328 SCHI0034.S.7 and SCHI0034.S.9 (Figure 3); the latter pair were retrieved from a BW and sputum

329 collected on the same day (Table S1; Table S3). The only exception was *P. melaninogenica* from

330 SCHI0027, where two genetically distinct lineages separated by >20k SNPs were retrieved from this

331 participant. There was no evidence of genetically-related strains between any of the Australian

332 participants for any *Prevotella* spp. (Figure 3). These findings indicate that interhost diversity is very

333 high, whereas within-host Prevotella diversity is limited, possibly due to frequent microaspiration of

334 *Prevotella* from upper to lower airways (or via the gut-lung axis) rather than chronic infection;

335 however, more in-depth sampling is required to investigate *Prevotella* persistence.

336 Antibiotics are routinely used in the maintenance and treatment of acute respiratory infections in CF and COPD^{15,59}. Given its uncertain pathogenic role, *Prevotella* spp. are not targeted by these 337 338 treatment regimens⁶⁰. Despite this, AMR rates in *Prevotella* are trending upwards⁵⁹, possibly due to 339 bystander selection. To examine this phenomenon, we determined AMR profiles for all culturable 340 Prevotella strains (n=27) using disc diffusion against 11 antibiotics commonly used to treat lung infections^{15,59}, or which have known activity against anaerobic taxa⁴⁷. AMR (AZM, CAZ, CLI, MZ, 341 342 TOB) or reduced susceptibility (AMC, AZM, CAZ, DOX, MEM) was observed in at least one strain, 343 whereas all were susceptible towards CHL, TZP, and IPM, an observation supported by previous studies^{47,59,61}. Reflecting much greater lifetime antimicrobial use in the CF cohort⁶², the 18 tested CF 344 345 strains had much higher AMR incidence (57% vs. 8%) and AMR gene presence (83% vs. 35%) 346 compared with COPD strains, and this rate increased to 100% (69% for COPD) when including 347 strains with reduced susceptibility towards one or more antibiotics (Table 2). In addition, almost all CF 348 participants were undergoing antimicrobial treatment with at least two different antibiotic classes at 349 the time of sample collection, vs. almost no antibiotic use in the COPD participants (Table S1). One 350 strain, CF isolate P. histicola SCHI0009.S.6, could be classed as multidrug-resistant due to exhibiting AMR towards three antibiotic classes⁶³ – β -lactams, lincosamides, and imidazoles – along with 351 352 reduced susceptibility towards the tetracycline-class antibiotic, DOX (Table 2). Our findings confirm 353 bystander AMR selection in off-target Prevotella as a direct result of heavy antimicrobial use in CF 354 (and to a much lesser extent, COPD), which may have ramifications for Prevotella persistence as a 355 potential driver of disease pathogenesis. 356 TOB was the only antibiotic tested that showed AMR in all tested isolates, including the type strain, P. 357 melaninogenica LMG 28911 (Table 2). This finding that concurs with prior work reporting 100% TOB

resistance among 157 *Prevotella* isolates⁵⁹. A CF microbiome study also found that *Prevotella*

abundance was largely unchanged upon TOB treatment⁶⁴. These collective findings indicate that all

360 respiratory *Prevotella* species are intrinsically resistant to TOB. Notably, we observed that the median

- 361 relative *Prevotella* abundance according to metataxonomics was quite different between CF (9.6%)
- 362 vs. COPD (0.6%) specimens (**Table S3**). Although the basis of this higher relative *Prevotella*

363 abundance in CF is unknown, one possibility is that most of our CF participants were receiving TOB

at the time of sample collection (Table S1; Table 2), whereas no COPD participant was receiving this

365 antibiotic. The predominance of *Prevotella* spp. in the CF airways might thus be attributed to much

more frequent TOB use in this cohort⁶⁵⁻⁶⁷. Although not assessed in this study, adding TOB to
selective media may improve *Prevotella* recovery rates from respiratory specimens by suppressing
growth of other taxa. After TOB, CLI resistance was most common (6/14 CF isolates), followed by
AZM (4/14 CF isolates), MZ (1/13 COPD and 3/14 CF isolates), and CAZ (2/14 CF isolates).
Decreased susceptibility towards AMC, CAZ, and DOX was common in both CF and COPD isolates;
however, only CF isolates exhibited decreased AZM susceptibility (6/14 isolates). These results

373 in CF-derived isolates.

374 AMR genes represent a major concern in infection control as these genes can rapidly transfer AMR 375 among different genera and species. To determine AMR gene potential, CARD analysis was 376 performed on the 35 CF-COPD Prevotella genomes and used to correlate horizontally acquired AMR-377 conferring genes with AMR/decreased susceptibility phenotypes. Consistent with their higher AMR 378 rates, CF isolates demonstrated greater prevalence of AMR-conferring genes compared with COPD 379 (Table 2). Strikingly, 67% CF strains encoded *ermF*, a horizontally-acquired gene that confers 380 resistance towards macrolide, lincosamide, and streptogramin-class antibiotics such as AZM and CLI^{47,61,68}. In contrast, *ermF* was absent in all COPD strains, a somewhat unexpected finding given 381 382 that COPD participants are frequently given long-term macrolides (e.g. azithromycin, erythromycin) as 383 prophylaxis to reduce exacerbation frequency⁶⁹. None of the CF or COPD participants were receiving 384 these antibiotics at the time of sample collection, suggesting that cross-resistance or prior CF 385 antibiotic treatment may be driving *ermF* acquisition and maintenance in *Prevotella*. *ermF* presence 386 correlated well with AZM and CLI AMR/decreased susceptibility (87% and 75%, respectively). ermF 387 rates in our Australian isolates exceed those previously reported (23-68% in UK, USA, and Italian isolates from both healthy and diseased participants)^{68,70}. This discrepancy is likely due to only 388 389 respiratory disease-associated isolates being tested in our study, but may also be due to differences 390 in AMR cut-offs between studies, in vivo antibiotic exposure levels, and potentially species or strain 391 composition, noting that one study only identified most isolates to the genus level⁶⁸. tetQ, which confers resistance to tetracycline-class antibiotics (e.g. DOX)^{68,70}, was present in 54% of 392

our strains, and more common in CF-derived strains (67% vs. 41%). This rate is much higher than tetQ prevalence reported in UK CF $(21\%)^{68}$ and human-derived Dutch $(30\%)^{61}$ strains. Our *tet*Q-

harbouring strains consistently showed much smaller DOX disc diameters (12-30mm; median 22mm)

396 compared with tetQ-negative strains (40-64mm; median 54mm) with 100% correlation between tetQ 397 presence and decreased DOX susceptibility (Table 2). A prior study reported that 83% of tetQ-398 positive isolates demonstrated intermediate or full resistance towards tetracycline⁶⁸, suggesting that 399 tetQ is a reliable marker of reduced susceptibility towards tetracycline-class antibiotics. Taken 400 together, these results confirm that tetQ presence robustly confers decreased DOX susceptibility in 401 Prevotella spp. Although our dataset is small, we propose Prevotella spp. DOX disc diameters of 402 \geq 40mm to denote strains lacking tetQ, and \leq 30mm to denote strains that may be harbouring tetQ, with 403 the caveat that other enigmatic determinants conferring reduced DOX susceptibility (e.g. 404 chromosomal mutations) may be present in lieu of tetQ. These criteria also differentiate Prevotella 405 spp. exhibiting decreased DOX susceptibility from DOX-sensitive strains. The *cfxA*-type β-lactamase gene is the most clinically important AMR mechanism in *Prevotella* spp.⁷¹ 406 as it confers AMR towards cephamycins⁶¹ and some other β-lactam antibiotics⁶⁸, which are commonly 407 used in respiratory infection treatment⁵⁹. Concerningly, *cfxA* is often encoded on mobile elements, 408 409 meaning that AMR can potentially be transmitted from *Prevotella* spp. to known pathogenic taxa in the respiratory microbiome⁷². We found cfxA alleles 2, 3, 4, and/or 5 in 54% strains (72% CF and 35% 410 411 COPD). cfxA3 and cfxA2 were most common, being present in 37% and 14% strains, respectively. In 412 comparison, a study of UK and US isolates reported much higher cfxA carriage rates (86%), with 29% 413 and 52% strains encoding cfxA3 and cfxA2, respectively. Their study also found that cfxA3-encoding isolates exhibited significantly higher CAZ resistance levels⁶⁸, which we also observed in our *cfxA*3-414 415 harbouring strains (median disc diameter=12mm vs. 32mm in non-cfxA3 strains) (Table 2). In cfxA3encoding strains displaying CAZ sensitivity, reduced *cfxA3* expression⁷³ may explain this phenotype, 416 417 although this was not explored in our study. In addition, we did not test Prevotella susceptibility 418 towards cephamycins so were unable to determine whether cfxA variants correlated with these β-419 lactam antibiotics. 420 MZ resistance was evident in 4/28 tested strains (3 CF; 1 COPD), despite none of the participants 421 receiving nitroimidazoles at the time of sample collection. Other than TOB, MZ was the only antibiotic 422 that exhibited AMR in any of the COPD strains. The *nim* genes, which encode for nitroimidazole reductase enzymes and have previously been associated with MZ resistance in *P. baroniae*⁷⁴ and *P.* 423

unknown.

bivia⁷⁵, were not detected in any isolate. Therefore, the basis of MZ resistance in our isolates remains

424

425

426 Of the eight species identified in our study, four are conventionally considered dark-pigmented -P. 427 denticola, P. histicola, P. melaninogenica, and P. nigrescens. Pigmented Prevotella reportedly 428 harbour a greater cache of virulence factors and are more commonly associated with infection⁴⁷. 429 However, we found limited phenotypic differences within and between species on non-selective 430 anaerobic blood medium at Day 3 (Figure 4), with most presenting as convex, shiny, white colonies; 431 only *P. nigrescens* demonstrated tan pigmentation in the primary streak at this time point (Figure 4F). 432 In contrast, a dark brown to black pigment was produced by P. nigrescens on PVCA by Day 3 (Figure 433 5D), but not on selective or non-selective anaerobic media, even by Day 10, with only medium-brown 434 colonies present (Figure 5B and 5C). P. histicola demonstrated tan-coloured pigmentation on both 435 non-selective anaerobic medium and PVCA, but only after five days (Figure 6), and unlike P. 436 nigrescens, did not develop black pigment on PVCA at Days 5 or 10. P. melaninogenica reportedly produces a characteristic dark pigment that is commonly associated with the species^{76,77}; yet, no 437 438 pigmentation was observed in the six P. melaninogenica isolates on any medium by Day 10. A likely 439 explanation for this phenomenon is that different strains require different media for pigment 440 production⁷⁸. Collectively, the limited pigmentation observed among *Prevotella* spp. suggests that 441 phenotypic characteristics alone should not be used for Prevotella genus or species identification. 442 We acknowledge several study limitations. First, small sample size (43 enrolled participants; 69 443 samples) and inclusion of only COPD and CF samples makes it difficult to generalise our results 444 across a larger cohorts. Nevertheless, the broad agreement of our findings with previous literature^{10,14,19} demonstrates a reasonable estimation of species diversity in these cohorts. Second, 445 446 due to non-anaerobic sample handling and storage, non-aerotolerant Prevotella species may have 447 been rendered non-viable and thus not recoverable⁴⁵. Future establishment of disc diffusion 448 guidelines in *Prevotella* will enable more accurate assessment of AMR phenotypes in this genus. 449 Third, due to our use of a strict AMR cut-off (i.e. 6mm), AMR rates in our Prevotella are almost 450 certainly underestimated. Fourth, we did not assess healthy airway microbiota due to difficulties 451 associated with obtaining respiratory secretions from healthy participants. Future work should 452 continue to seek strain-level resolution of *Prevotella* strains in CF and COPD airways, including the 453 design of species-specific assays towards commonly isolated and known pathogenic species, 454 assessment of Prevotella from healthy airways, and incorporation of higher-resolution molecular 455 technologies such as metagenomics and metatranscriptomics to gain a clearer understanding of

- 456 Prevotella function within complex microbiomes. Co-culture experiments between Prevotella species
- 457 and known respiratory pathogens, such as *P. aeruginosa*, would be beneficial for elucidating the role
- 458 of Prevotella in potentiating or abrogating pathogen virulence. Finally, phylogeographic analysis of
- 459 Prevotella genomes may permit a deeper understanding of Prevotella spp. distribution and strain
- 460 diversity in chronic lung disease globally, and population genomic approaches will yield a better
- 461 understanding of *Prevotella* origin and capacity for airway-to-airway transmission.

462 Acknowledgements

- 463 We thank Tamieka Fraser (University of the Sunshine Coast) for laboratory assistance, Peter Timms
- 464 (University of the Sunshine Coast) and Laura Sherrard (Queen's University Belfast) for insightful
- 465 feedback on this manuscript, Tania Duarte (University of Queensland) for helpful discussions about
- the challenges of *Prevotella* identification using current metagenomic pipelines, and the Belgian Co-
- 467 ordinated Collection of Micro-organisms (BCCM) for providing type strains. This work was funded by
- 468 Advance Queensland (awards AQRF13016-17RD2 and AQIRF0362018), the Wishlist Sunshine
- 469 Coast Hospital Foundation (award 2019-24), and the University of the Sunshine Coast. The authors
- 470 declare no conflicts of interest.

471 Figure legends

- 473 **Figure 1**. Limits of detection (LoD) and quantification (LoQ) for the *Prevotella* real-time PCR assay.
- 474 The LoQ and LoD were both 400fg/µL according to previously defined parameters³⁵, or 111 genome
- 475 equivalents.
- 476 Figure 2. Full-length 16S ribosomal RNA gene phylogenetic analysis of the 35 Prevotella strains
- 477 retrieved in this study (identified by 'SCHI' prefix) against 199 non-redundant public Prevotella
- 478 genomes comprising 56 taxa of known species and 40 taxa of unassigned species. Species clades
- 479 containing isolates identified from our cystic fibrosis (CF) and chronic obstructive pulmonary disease
- 480 (COPD) specimens are coloured.
- 481 Figure 3. Maximum parsimony within-species phylogenomic reconstruction of *P. denticola*, *P.*
- 482 histicola, P. melaninogenica, P. nanceiensis and P. salivae. Strains identified from COPD and CF
- 483 specimens from this study are labelled with the 'SCHI' prefix; the remaining strains are public
- 484 genomes. The number of SNPs separating each strain is labelled on branches; where two or more
- 485 strains were retrieved from a single participant, coloured branch labels represent the number of SNPs
- separating these strains. CI, consistency index. Incorrectly speciated public genomes are denoted byan asterisk.
- 488 Figure 4. Three-day growth of *Prevotella* spp. on non-selective anaerobic blood medium. (A) *P*.
- 489 melaninogenica; (B) P. histicola; (C) P. denticola; (D) P. nanceiensis; (E) P. jejuni; (F) P. nigrescens;
- 490 (G) P. salivae; and (H) P. buccae.
- Figure 5. Phenotype comparison of *Prevotella nigrescens* on non-selective anaerobic blood medium
 (top) and polyvitaminic-supplemented chocolate agar (bottom) at (A and D) 3 days; (B and E) 5 days;
- 493 and (C and F) 10 days.
- Figure 6. Phenotype comparison of *Prevotella histicola* on non-selective anaerobic blood medium
 (top) and polyvitaminic-supplemented chocolate agar (bottom) at (A and C) 3 days and (B and D) 5
 days.

497 Tables

- 498 **Table 1.** *Prevotella* spp. prevalence in cystic fibrosis (CF) and chronic obstructive pulmonary disease
- 499 (COPD) according to microbiological culture, real-time PCR, and 16S rRNA gene metataxonomics.

	Prevotella +ve	CF	COPD
ants	Culture	11/21 (52%)	6/21 (29%)
Participants	PCR	17/21 (81%)	15/21 (71%)
Part	Metataxonomics	15/17 (88%)	16/18 (89%)
sus	Culture	16/36 (44%)	9/32 (28%)
Specimens	PCR	29/36 (81%)	21/32 (66%)
Spe	Metataxonomics	26/31 (84%)	20/22 (91%)

501 **Table 2.** Disc diffusion and antimicrobial resistance gene results for genome-sequenced *Prevotella* isolates from cystic fibrosis (CF) or chronic obstructive

502 pulmonary disease (COPD) respiratory secretions, and antibiotic treatment at time of isolate collection.

	Prevotella sp. ¥	Antibiotic disc diffusion diameter (mm) by antibiotic class												
Strain ID		Macrolide- lincosamides		Tetra- cyclines	Other			β-lactams					cfxA allele	Antibiotic treatment [‡]
		AZM	CLI	DOX	CHL	MZ	тов	AMC	CAZ	TZP	IPM	MEM		
CF-derived isolate	es						4		4					
SCHI0006.S.13	P. histicola	50	60	24*	42	50	6	70	52	64	60	58	Neg	Nil
SCHI0009.S.5	P. melaninogenica	6 [†]	6^{\dagger}	22*	34	38	6	30	30	50	60	46	Neg	FOF, TOB
SCHI0009.S.6	P. histicola	6 [†]	6 [†]	16*	32	6	6	50	40	48	60	44	Neg	FOF, TOB
SCHI0010.S.3	P. nanceiensis	nt [†]	nt [†]	nt*	nt	nt	nt	nt	nt	nt	nt	nt	cfxA3	CAZ, TOB
SCHI0011.S.12	P. nanceiensis	32	40	14*	34	6	6	20	6	44	56	46	cfxA3	CAZ, TOB
SCHI0011.S.13	P. jejuni	46	48	20*	34	46	6	34	32	52	62	40	Neg	CAZ, TOB
SCHI0018.S.9	P. salivae	nt^\dagger	nt [†]	nt*	nt	nt	nt	nt	nt	nt	nt	nt	cfxA3	CAZ, TZP, TOB
SCHI0021.S.9	P. denticola	6 [†]	6 [†]	24*	34	58	6	24	10	46	54	44	cfxA4	CAZ, TOB
SCHI0027.S.6	P. melaninogenica	26	52	44	32	42	6	24	14	42	54	46	Neg	CAZ, TOB
SCHI0027.S.7	P. histicola	6 [†]	6 [†]	50	34	40	6	14	10	48	50	46	cfxA3	CAZ, TOB
SCHI0027.S.9	P. melaninogenica	42 [†]	34^{\dagger}	40	44	6	6	48	40	52	64	50	cfxA3	CAZ, TOB
SCHI0027.S.11	P. melaninogenica	nt [†]	nt [†]	nt	nt	nt	nt	nt	nt	nt	nt	nt	cfxA3	CAZ, TOB
SCHI0027.S.12	P. denticola	8†	6 [†]	20*	34	44	6	10	6	38	46	38	cfxA3	CAZ, TOB
SCHI0027.S.13	P. melaninogenica	nt [†]	nt [†]	nt	nt	nt	nt	nt	nt	nt	nt	nt	cfxA3	CAZ, TOB
SCHI0027 .S.14	P. denticola	14 [†]	6^{\dagger}	56	42	50	6	14	8	48	48	40	cfxA3	CAZ, TOB
SCHI0028.S.1	P. histicola	18	54	14*	38	40	6	50	32	44	60	26	cfxA2	MEM, TOB
SCHI0028.S.4	P. histicola	20	64	24*	48	44	6	26	34	56	62	40	cfxA2	MEM, TOB
SCHI0028.S.5	P. nigrescens	10 [†]	50^{\dagger}	30*	50	60	6	36	24	50	56	50	cfxA2	MEM, TOB
COPD-derived iso	lates													
SCHI0034.S.5	P. histicola	52	70	64	50	60	6	66	58	66	60	50	Neg	Nil
SCHI0034.S.6	P. histicola	44	60	58	42	50	6	58	50	58	58	50	Neg	Nil
SCHI0034.S.7	P. melaninogenica	40	48	12*	34	38	6	48	20	46	52	54	cfxA3	Nil
SCHI0034.S.8	P. salivae	38	54	20*	36	46	6	50	20	50	54	48	Neg	Nil
SCHI0034.S.9	P. melaninogenica	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	cfxA3	Nil
SCHI0034.S.10	P. histicola	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	Neg	Nil
SCHI0034.S.11	P. salivae	46	50	20*	36	44	6	48	26	48	52	52	Neg	Nil
SCHI0042.S.4	P. denticola	38	46	24*	36	46	6	18	14	44	50	42	cfxA2,	AMX

													cfxA5	
SCHI0042.S.5	P. nanceiensis	30	36	26*	34	6	6	14	12	36	52	52	cfxA3	AMX
SCHI0043.S.1	P. melaninogenica	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	Neg	Nil
SCHI0043.S.2	P. melaninogenica	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	nt	Neg	Nil
SCHI0043.S.3	P. melaninogenica	36	44	54	36	48	6	50	34	50	58	50	Neg	Nil
SCHI0044.S.1	P. melaninogenica	34	56	60	42	48	6	30	24	56	58	52	Neg	Nil
SCHI0047.S.2	P. melaninogenica	40	48	24*	32	48	6	18	12	50	50	46	cfxA2	Nil
SCHI0047.S.3	P. salivae	40	48	24*	32	48	6	18	12	50	50	46	Neg	Nil
SCHI0047.S.4	P. buccae	46	58	54	42	52	6	52	38	58	56	50	Neg	Nil
SCHI0049.S.1	P. melaninogenica	44	58	58	44	50	6	24	20	58	60	52	cfxA3	Nil
LMG 28911 (type strain)	P. melaninogenica	40	54	50	36	46	6	50	50	54	52	38	Unknown	Unknow

503 Abbreviations: AMC, amoxicillin-clavulanate; AMX, amoxicillin; AZM, azithromycin; CAZ, ceftazidime; CHL, chloramphenicol; CLI, clindamycin; DOX,

504 doxycycline; FOF, fosfomycin; IPM, imipenem; MEM, meropenem; MZ, metronidazole; Neg, negative; nt, not tested for antimicrobial sensitivity; TZP,

- 505 piperacillin-tazobactam; TOB, tobramycin
- 506 Dark grey-shaded cells represent definitive antimicrobial resistance (i.e. growth right up to the disc), light grey-shaded cells reflect reduced susceptibility
- 507 (<30mm diameter), and unshaded cells represent probable sensitivity (>30mm diameter)
- [†]Encodes *ermF*, which confers resistance towards erythromycin⁷⁰
- ⁵⁰⁹ [‡]At time of clinical specimen collection from which the isolate was derived
- ⁵¹⁰ *Encodes *tetQ*, which is associated with decreased susceptibility/resistance towards tetracycline-class antibiotics^{68,70} such as DOX
- 511 [¥]As determined from whole-genome sequence analysis

512 References

513	1. Sze MA, Hogg JC, Sin DD. Bacterial microbiome of lungs in COPD. Int J Chron Obstruct Pulmon Dis
514	2014; 9 : 229-38.
515	2. Fenker DE, McDaniel CT, Panmanee W, et al. A comparison between two pathophysiologically different
516	yet microbiologically similar lung diseases: cystic fibrosis and chronic obstructive pulmonary disease. Int J Respir
517	Pulm Med 2018; 5(2).
518 519	3. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. <i>Lancet</i> 2007; 370 (9589): 786-96.
520	 Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev
521	2002; 15 (2): 194-222.
522	 Jacobs DM, Pandit U, Sethi S. Acute exacerbations in chronic obstructive pulmonary disease: should
523	we use antibiotics and if so, which ones? <i>Curr Opin Infect Dis</i> 2019; 32 (2): 143-51.
524	6. Larsen JM. The immune response to <i>Prevotella</i> bacteria in chronic inflammatory disease. <i>Immunology</i>
525	2017; 151 (4): 363-74.
526	7. Gilpin DF, Nixon KA, Bull M, et al. Evidence of persistence of <i>Prevotella</i> spp. in the cystic fibrosis lung. J
527	Med Microbiol 2017; 66(6): 825-32.
528	8. Ditz B, Christenson S, Rossen J, et al. Sputum microbiome profiling in COPD: beyond singular
529	pathogen detection. <i>Thorax</i> 2020; 75 (4): 338-44.
530	9. Pattison SH, Rogers GB, Crockard M, Elborn JS, Tunney MM. Molecular detection of CF lung
531	pathogens: current status and future potential. J Cyst Fibros 2013; 12(3): 194-205.
532	10. Lee SW, Kuan CS, Wu LS, Weng JT. Metagenome and metatranscriptome profiling of moderate and
533	severe COPD sputum in Taiwanese Han males. <i>PLoS One</i> 2016; 11 (7): e0159066.
534 535	11. Muhlebach MS, Hatch JE, Einarsson GG, et al. Anaerobic bacteria cultured from cystic fibrosis airways
535 536	 correlate to milder disease: a multisite study. <i>Eur Respir J</i> 2018; 52(1). 12. Amat S, Lantz H, Munyaka PM, Willing BP. <i>Prevotella</i> in pigs: the positive and negative associations
537	with production and health. <i>Microorganisms</i> 2020; 8 (10).
538	13. Wybo I, Soetens O, De Bel A, et al. Species identification of clinical <i>Prevotella</i> isolates by matrix-
539	assisted laser desorption ionization-time of flight mass spectrometry. <i>J Clin Microbiol</i> 2012; 50 (4): 1415-8.
540	14. Tunney MM, Field TR, Moriarty TF, et al. Detection of anaerobic bacteria in high numbers in sputum
541	from patients with cystic fibrosis. Am J Respir Crit Care Med 2008; 177 (9): 995-1001.
542	15. Cuthbertson L, Walker AW, Oliver AE, et al. Lung function and microbiota diversity in cystic fibrosis.
543	Microbiome 2020; 8 (1): 45.
544	16. Han MK, Huang YJ, Lipuma JJ, et al. Significance of the microbiome in obstructive lung disease. <i>Thorax</i>
545	2012; 67 (5): 456-63.
546	17. Wang Z, Maschera B, Lea S, et al. Airway host-microbiome interactions in chronic obstructive
547	pulmonary disease. Respir Res 2019; 20 (1): 113.
548	18. Mirkovic B, Murray MA, Lavelle GM, et al. The role of short-chain fatty acids, produced by anaerobic
549	bacteria, in the cystic fibrosis airway. Am J Respir Crit Care Med 2015; 192 (11): 1314-24.
550 551	19. Field TR, Sibley CD, Parkins MD, Rabin HR, Surette MG. The genus <i>Prevotella</i> in cystic fibrosis
552	 airways. Anaerobe 2010; 16(4): 337-44. 20. Ulrich M, Beer I, Braitmaier P, et al. Relative contribution of <i>Prevotella intermedia</i> and <i>Pseudomonas</i>
553	aeruginosa to lung pathology in airways of patients with cystic fibrosis. Thorax 2010; 65 (11): 978-84.
554	21. Jorth P, Ehsan Z, Rezayat A, et al. Direct lung sampling indicates that established pathogens dominate
555	early infections in children with cystic fibrosis. <i>Cell Rep</i> 2019; 27 (4): 1190-204.
556	22. Zemanick ET, Wagner BD, Sagel SD, Stevens MJ, Accurso FJ, Harris JK. Reliability of quantitative real-
557	time PCR for bacterial detection in cystic fibrosis airway specimens. PLoS One 2010; 5(11): e15101.
558	23. O'Neill K, Bradley JM, Johnston E, et al. Reduced bacterial colony count of anaerobic bacteria is
559	associated with a worsening in lung clearance index and inflammation in cystic fibrosis. <i>PLoS One</i> 2015; 10 (5):
560	e0126980.
561	24. Einarsson GG, Zhao J, LiPuma JJ, Downey DG, Tunney MM, Elborn JS. Community analysis and co-
562	occurrence patterns in airway microbial communities during health and disease. ERJ Open Res 2019; 5(3).
563	25. Wang Z, Liu H, Wang F, et al. A refined view of airway microbiome in chronic obstructive pulmonary
564	disease at species and strain-levels. Front Microbiol 2020; 11: 1758.
565 566	26. Human Microbiome Jumpstart Reference Strains Consortium. A catalog of reference genomes from the
567	human microbiome. <i>Science</i> 2010; 328 (5981): 994-9. 27. Gupta VK. Chaudhari NM. Iskepalli S. Dutta C. Divergences in gene repertoire among the reference
568	27. Gupta VK, Chaudhari NM, Iskepalli S, Dutta C. Divergences in gene repertoire among the reference <i>Prevotella</i> genomes derived from distinct body sites of human. <i>BMC Genomics</i> 2015; 16 : 153.
569	28. Zhang Y, Zhen M, Zhan Y, Song Y, Zhang Q, Wang J. Population-genomic insights into variation in
570	Prevotella intermedia and Prevotella nigrescens isolates and its association with periodontal disease. Front Cell
571	Infect Microbiol 2017; 7: 409.
572	29. Tett A, Huang KD, Asnicar F, et al. The <i>Prevotella copri</i> complex comprises four distinct clades
573	underrepresented in Westernized populations. Cell Host Microbe 2019; 26(5): 666-79.
574	30. de Lamballerie X, Zandotti C, Vignoli C, Bollet C, de Micco P. A one-step microbial DNA extraction

575 method using "Chelex 100" suitable for gene amplification. *Res Microbiol* 1992; **143**(8): 785-90.

576 31. Triant DA, Whitehead A. Simultaneous extraction of high-guality RNA and DNA from small tissue 577 samples. J Hered 2009: 100(2): 246-50. 578 Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 32 579 1990; **215**(3): 403-10. 580 Klaassen CH, Jeunink MA, Prinsen CF, et al. Quantification of human DNA in feces as a diagnostic test 33. 581 for the presence of colorectal cancer. Clin Chem 2003; 49(7): 1185-7. 582 34. Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology (Reading) 2002; 148(Pt 1): 257-66. 583 584 35. Price EP. Dale JL. Cook JM. et al. Development and validation of Burkholderia pseudomallei-specific 585 real-time PCR assays for clinical, environmental or forensic detection applications. PLoS One 2012; 7(5): 586 e37723. 587 36. Hudzicki J. Kirby-Bauer Disk Diffusion Susceptibility Test Protocol. 2016. 588 https://asm.org/Protocols/Kirby-Bauer-Disk-Diffusion-Susceptibility-Test-Pro (accessed 11Dec20). 589 Bankevich A, Nurk S, Antipov D, et al. SPAdes: a new genome assembly algorithm and its applications 37. 590 to single-cell sequencing. J Comput Biol 2012; 19(5): 455-77. 591 Jolley KA, Bliss CM, Bennett JS, et al. Ribosomal multilocus sequence typing: universal characterization 38 592 of bacteria from domain to strain. Microbiology (Reading) 2012; 158(Pt 4): 1005-15. 593 Larkin MA, Blackshields G, Brown NP, et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007; 39 594 23(21): 2947-8. 595 40. Sarovich DS, Price EP. SPANDx: a genomics pipeline for comparative analysis of large haploid whole 596 genome re-sequencing datasets. BMC Res Notes 2014; 7: 618. 597 Huang W, Li L, Myers JR, Marth GT. ART: a next-generation sequencing read simulator. Bioinformatics 41. 598 2012; 28(4): 593-4. 599 Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. 42 600 Bioinformatics 2014; 30(15): 2114-20. 601 Price EP, Viberg LT, Kidd TJ, Bell SC, Currie BJ, Sarovich DS. Transcriptomic analysis of longitudinal 43 602 Burkholderia pseudomallei infecting the cystic fibrosis lung. Microb Genom 2018; 4(8). 603 Alcock BP, Raphenya AR, Lau TTY, et al. CARD 2020: antibiotic resistome surveillance with the 44. 604 comprehensive antibiotic resistance database. Nucleic Acids Res 2020; 48(D1): D517-D25. 605 Silva VL, Carvalho MA, Nicoli JR, Farias LM. Aerotolerance of human clinical isolates of Prevotella spp. 45. 606 J Appl Microbiol 2003; 94(4): 701-7. 607 Aziz A, Currie BJ, Mayo M, Sarovich DS, Price EP. Comparative genomics confirms a rare melioidosis 46. 608 human-to-human transmission event and reveals incorrect phylogenomic reconstruction due to polyclonality. 609 Microb Genom 2020: 6(2). 610 47. Xie Y, Chen J, He J, et al. Antimicrobial resistance and prevalence of resistance genes of obligate 611 anaerobes isolated from periodontal abscesses. J Periodontol 2014; 85(2): 327-34. 612 Goddard AF, Staudinger BJ, Dowd SE, et al. Direct sampling of cystic fibrosis lungs indicates that DNA-48 613 based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci U S A 2012; 614 **109**(34): 13769-74. 615 49. Pragman AA, Lyu T, Baller JA, et al. The lung tissue microbiota of mild and moderate chronic 616 obstructive pulmonary disease. Microbiome 2018; 6(1): 7. 617 Dickson RP, Erb-Downward JR, Freeman CM, et al. Bacterial topography of the healthy human lower 50 618 respiratory tract. mBio 2017; 8(1). Bassis CM. Erb-Downward JR. Dickson RP, et al. Analysis of the upper respiratory tract microbiotas as 619 51. 620 the source of the lung and gastric microbiotas in healthy individuals. mBio 2015; 6(2): e00037. 621 Larsen JM, Steen-Jensen DB, Laursen JM, et al. Divergent pro-inflammatory profile of human dendritic 52. 622 cells in response to commensal and pathogenic bacteria associated with the airway microbiota. PLoS One 2012; 623 7(2): e31976. 624 Hedberg ME, Israelsson A, Moore ERB, et al. Prevotella jejuni sp. nov., isolated from the small intestine 53. 625 of a child with coeliac disease. Int J Syst Evol Microbiol 2013; 63(Pt 11): 4218-23. 626 Enaud R, Prevel R, Ciarlo E, et al. The gut-lung axis in health and respiratory diseases: a place for inter-54 627 organ and inter-kingdom crosstalks. Front Cell Infect Microbiol 2020; 10: 9. 628 Bertelsen A, Elborn SJ, Schock BC. Toll like Receptor signalling by Prevotella histicola activates 55. 629 alternative NF-kappaB signalling in cystic fibrosis bronchial epithelial cells compared to P. aeruginosa. PLoS One 630 2020; 15(10): e0235803. 631 Di Lorenzo F, Silipo A, Matier T, et al. Prevotella denticola lipopolysaccharide from a cystic fibrosis 56. 632 isolate possesses a unique chemical structure. European J Org Chem 2016; 9: 1732-8. 633 Yanagisawa M, Kuriyama T, Williams DW, Nakagawa K, Karasawa T. Proteinase activity of Prevotella 57. 634 species associated with oral purulent infection. Curr Microbiol 2006; 52(5): 375-8. 635 Alauzet C, Marchandin H, Lozniewski A. New insights into Prevotella diversity and medical microbiology. 58 636 Future Microbiol 2010; 5(11): 1695-718. 637 59. Sherrard LJ, Graham KA, McGrath SJ, et al. Antibiotic resistance in Prevotella species isolated from 638 patients with cystic fibrosis. J Antimicrob Chemother 2013; 68(10): 2369-74. 639 Brill SE, Law M, El-Emir E, et al. Effects of different antibiotic classes on airway bacteria in stable COPD 60. 640 using culture and molecular techniques: a randomised controlled trial. Thorax 2015; 70(10): 930-8. 641 Veloo ACM, Baas WH, Haan FJ, Coco J, Rossen JW. Prevalence of antimicrobial resistance genes in 61. 642 Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect 2019; 25(9): 1156 e9- e13.

643 Sherrard LJ, Tunney MM, Elborn JS. Antimicrobial resistance in the respiratory microbiota of people with 62. 644 cystic fibrosis. Lancet 2014; 384(9944): 703-13. 645 Hahn A, Burrell A, Fanous H, et al. Antibiotic multidrug resistance in the cystic fibrosis airway 63. 646 microbiome is associated with decreased diversity. Heliyon 2018; 4(9): e00795. 647 Nelson MT, Wolter DJ, Eng A, et al. Maintenance tobramycin primarily affects untargeted bacteria in the 64. 648 CF sputum microbiome. Thorax 2020; 75(9): 780-90. 649 Bittar F, Richet H, Dubus JC, et al. Molecular detection of multiple emerging pathogens in sputa from 65. 650 cystic fibrosis patients. PLoS One 2008; 3(8): e2908. 651 Shakil S, Khan R, Zarrilli R, Khan AU. Aminoglycosides versus bacteria--a description of the action, 66. 652 resistance mechanism, and nosocomial battleground. J Biomed Sci 2008; 15(1): 5-14. 653 Thornton CS, Surette MG. Potential contributions of anaerobes in cystic fibrosis airways. J Clin Microbiol 67. 654 2021; 59(3) 655 68 Sherrard LJ, Schaible B, Graham KA, et al. Mechanisms of reduced susceptibility and genotypic 656 prediction of antibiotic resistance in *Prevotella* isolated from cystic fibrosis (CF) and non-CF patients. J 657 Antimicrob Chemother 2014; 69(10): 2690-8. 658 Parameswaran GI, Sethi S. Long-term macrolide therapy in chronic obstructive pulmonary disease. 69 659 CMAJ 2014; 186(15): 1148-52. 660 Arzese AR. Tomasetia L. Botta GA. Detection of tetQ and ermF antibiotic resistance genes in Prevotella 70. 661 and Porphyromonas isolates from clinical specimens and resident microbiota of humans. J Antimicrob 662 Chemother 2000; 45(5): 577-82. 663 Fernández-Canigia L, Cejas D, Gutkind G, Radice M. Detection and genetic characterization of beta-71. 664 lactamases in Prevotella intermedia and Prevotella nigrescens isolated from oral cavity infections and 665 peritonsillar abscesses. Anaerobe 2015; 33: 8-13.

Sherrard LJ, McGrath SJ, McIlreavey L, et al. Production of extended-spectrum β-lactamases and the
 potential indirect pathogenic role of *Prevotella* isolates from the cystic fibrosis respiratory microbiota. *Int J Antimicrob Agents* 2016; 47(2): 140-5.

Jolivet-Gougeon A, Tamanai-Shacoori Z, Desbordes L, Burggraeve N, Cormier M, Bonnaure-Mallet M.
 Genetic analysis of an ambler class A extended-spectrum beta-lactamase from *Capnocytophaga ochracea*. J
 Clin Microbiol 2004; 42(2): 888-90.

Alauzet C, Mory F, Teyssier C, et al. Metronidazole resistance in *Prevotella* spp. and description of a
 new *nim* gene in *Prevotella baroniae*. *Antimicrob Agents Chemother* 2010; **54**(1): 60-4.


Veloo ACM, Chlebowicz M, Winter HLJ, Bathoorn D, Rossen JWA. Three metronidazole-resistant
 Prevotella bivia strains harbour a mobile element, encoding a novel *nim* gene, *nimK*, and an efflux small MDR
 transporter. *J Antimicrob Chemother* 2018; **73**(10): 2687-90.

677 76. Allison HE, Hillman JD. Cloning and characterization of a *Prevotella melaninogenica* hemolysin. *Infect* 678 *Immun* 1997; **65**(7): 2765-71.


T7. Zhou X, Li Y. Subgingival microbes: from healthy microflora to disease. Atlas of Oral Microbiology:
 Elsevier; 2015.


Finegold SM. Anaerobic Gram-negative bacilli (Chapter 20). In: Baron S, ed. Medical Microbiology (4th
 edition). Galveston, TX: University of Texas Medical Branch at Galveston; 1996.

Amplification



Standard Curve





CI=0.81

CI=0.82

Prevotella melaninogenica

